Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ESIMIL vs COLESTIPOL HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Fixed-dose combination of olmesartan, amlodipine, and hydrochlorothiazide. Olmesartan is an angiotensin II receptor blocker (ARB) that inhibits vasoconstriction and aldosterone secretion. Amlodipine is a dihydropyridine calcium channel blocker that inhibits calcium influx into vascular smooth muscle, causing vasodilation. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal tubule.
Binds bile acids in the intestine, forming an insoluble complex that is excreted in feces, thereby reducing enterohepatic circulation and increasing hepatic conversion of cholesterol to bile acids, lowering serum LDL cholesterol.
Hypertension (to lower blood pressure, not for initial therapy)
Primary hypercholesterolemia (FDA-approved adjunct to diet),Pruritus associated with partial biliary obstruction,Pseudomembranous enterocolitis (off-label, as colestipol binds Clostridium difficile toxins),Digitoxin toxicity (off-label, to interrupt enterohepatic circulation),Bile acid malabsorption (off-label)
5 mg orally once daily, may increase to 10 mg once daily after 2-4 weeks if needed.
Initial: 5 g orally once daily or 2.5 g twice daily; increase gradually by 5 g/day at 1-2 month intervals; maintenance: 5-30 g/day divided once or twice daily; maximum: 30 g/day.
2.3 ± 0.4 hours; prolonged in renal impairment (up to 6.5 hours in severe cases).
Not applicable as colestipol is not absorbed; it acts locally in the gastrointestinal tract and has no systemic half-life.
Olmesartan: undergoes hepatic ester hydrolysis to active metabolite, not metabolized by CYP450 system. Amlodipine: extensively metabolized in liver via CYP3A4. Hydrochlorothiazide: not significantly metabolized.
Not metabolized; not absorbed systemically.
Primarily renal (>90% as unchanged drug); biliary/fecal <10%.
Colestipol hydrochloride is not absorbed systemically; it is excreted entirely in the feces as the intact polymer, without undergoing metabolism. No renal or biliary elimination occurs.
40-50% bound to albumin.
Not applicable; the drug is not absorbed and does not bind to plasma proteins.
1.5-2.0 L/kg; suggests extensive tissue distribution.
Not applicable; colestipol is not absorbed and remains within the gastrointestinal lumen.
Oral: 55-65% due to first-pass metabolism.
0% for systemic absorption; it is non-absorbable and acts locally in the intestine.
e GFR 30-89 m L/min: no adjustment. e GFR <30 m L/min: contraindicated.
No specific dose adjustment recommended; use with caution in severe renal impairment due to potential for hyperchloremic metabolic acidosis.
Child-Pugh A: no adjustment. Child-Pugh B: 2.5 mg once daily. Child-Pugh C: not recommended.
No specific dose adjustment recommended; caution in severe hepatic impairment due to possible decreased cholesterol synthesis.
Not approved for pediatric use; safety and efficacy not established.
Not established for children <10 years; for ≥10 years, initial: 5 g orally once daily; increase gradually to 5-20 g/day divided once or twice daily.
Start at 2.5 mg once daily due to increased sensitivity and risk of adverse effects.
No specific dose adjustment; monitor for gastrointestinal adverse effects and potential interactions with other medications due to altered GI motility and polypharmacy.
Discontinue as soon as possible when pregnancy is detected. Drugs acting directly on the renin-angiotensin system can cause injury and death to the developing fetus.
No FDA black box warning.
Fetal toxicity (see black box warning),Hypotension in volume-depleted patients,Monitor renal function; may increase serum creatinine and BUN,Electrolyte disturbances (hypokalemia, hyponatremia, hypercalcemia),Exacerbation of angina or acute MI (especially with rapid dose increase of amlodipine),Acute angle-closure glaucoma (with HCTZ),Systemic lupus erythematosus exacerbation (with HCTZ),Metabolic acidosis (with HCTZ),Avoid use in patients with severe renal impairment (Cr Cl <30 m L/min)
May cause hypertriglyceridemia,Risk of vitamin K deficiency and bleeding (due to bile acid binding),May impair absorption of fat-soluble vitamins (A, D, E, K),May cause constipation or fecal impaction (especially in elderly),May interfere with absorption of other drugs (e.g., warfarin, thyroid hormones, digoxin); separate administration by at least 1 hour or as specified
Hypersensitivity to any component,Anuria (due to HCTZ),Concomitant use with aliskiren in patients with diabetes
Hypersensitivity to colestipol hydrochloride or any component,Complete biliary obstruction,Phenylketonuria (if formulation contains aspartame)
Food may delay absorption; take on an empty stomach for best results. Avoid acidic beverages (e.g., orange juice) within 30 minutes of dosing. No significant food restrictions but a low-acid diet may help symptom control.
Colestipol can bind to dietary fats and fat-soluble vitamins (A, D, E, K). Take supplements at least 1 hour before or 4-6 hours after colestipol. High-fiber foods may reduce binding but are generally encouraged to prevent constipation. Avoid grapefruit juice? No significant interaction.
Esimil (pseudoephedrine) is classified as FDA Pregnancy Category C. In the first trimester, there is limited data but a potential risk of gastroschisis has been suggested in some retrospective studies. In the second and third trimesters, use may be associated with reduced uterine blood flow and fetal tachycardia; avoid near term due to risk of neonatal irritability. Overall, use only if clearly needed and after first trimester.
Colestipol hydrochloride is not absorbed systemically, thus no direct fetal exposure. No teratogenic risk expected. First trimester: minimal risk. Second/third trimester: no known adverse fetal effects.
Pseudoephedrine is excreted into breast milk in small amounts (M/P ratio ~2.5-3.5). It may reduce milk production, especially with chronic use. The relative infant dose is estimated at 2-5% of maternal weight-adjusted dose. Caution is advised; monitor infant for irritability, sleep disturbances, and feeding problems.
Colestipol is not absorbed systemically and not excreted into breast milk. Compatible with breastfeeding. M/P ratio not applicable.
No standard dose adjustments are recommended, but due to increased renal clearance in pregnancy, therapeutic effects may be reduced. Use the lowest effective dose for the shortest duration. Avoid sustained-release formulations in pregnancy due to unpredictable absorption.
No dose adjustment required due to lack of systemic absorption. Monitor for potential fat-soluble vitamin deficiency and supplement if needed.
ESIMIL (esomeprazole) is a proton pump inhibitor (PPI) used for acid-related disorders. Onset of action is rapid, but maximal acid suppression occurs after 5-7 days. Best taken before breakfast for optimal effect. Avoid co-administration with clopidogrel due to reduced efficacy. Monitor magnesium levels with prolonged use, especially in patients taking diuretics or digoxin. Consider calcium and vitamin D supplementation to mitigate osteoporosis risk.
Colestipol hydrochloride is a bile acid sequestrant used as adjunctive therapy for primary hyperlipidemia. It may increase triglyceride levels; monitor triglycerides before initiation. Administer other medications 1 hour before or 4-6 hours after colestipol to reduce absorption interference. Use with caution in constipation-prone patients; encourage high-fiber diet and adequate fluid intake. Can bind thyroxine, warfarin, digoxin, and fat-soluble vitamins.
Take this medication 30-60 minutes before a meal, preferably breakfast.,Swallow capsules whole; do not crush or chew.,Do not take with other acid reducers unless directed.,Report symptoms of severe diarrhea, bone pain, or muscle cramps.,Avoid alcohol and spicy foods that may worsen symptoms.,Long-term use may increase risk of fractures; ensure adequate calcium intake.
Take colestipol with meals and plenty of water (at least 8 oz).,Do not take other medications within 1 hour before or 4-6 hours after colestipol.,May cause constipation; increase dietary fiber and fluid intake.,Report severe constipation, abdominal pain, or unusual bleeding.,Continue prescribed diet and exercise regimen.,Store at room temperature; do not freeze.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ESIMIL vs COLESTIPOL HYDROCHLORIDE, answered by our medical review team.
ESIMIL is a Unknown that works by Fixed-dose combination of olmesartan, amlodipine, and hydrochlorothiazide. Olmesartan is an angiotensin II receptor blocker (ARB) that inhibits vasoconstriction and aldosterone secretion. Amlodipine is a dihydropyridine calcium channel blocker that inhibits calcium influx into vascular smooth muscle, causing vasodilation. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal tubule.. COLESTIPOL HYDROCHLORIDE is a Bile Acid Sequestrant that works by Binds bile acids in the intestine, forming an insoluble complex that is excreted in feces, thereby reducing enterohepatic circulation and increasing hepatic conversion of cholesterol to bile acids, lowering serum LDL cholesterol.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ESIMIL and COLESTIPOL HYDROCHLORIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ESIMIL is: 5 mg orally once daily, may increase to 10 mg once daily after 2-4 weeks if needed.. The standard adult dose of COLESTIPOL HYDROCHLORIDE is: Initial: 5 g orally once daily or 2.5 g twice daily; increase gradually by 5 g/day at 1-2 month intervals; maintenance: 5-30 g/day divided once or twice daily; maximum: 30 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ESIMIL and COLESTIPOL HYDROCHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ESIMIL is classified as Category C. Esimil (pseudoephedrine) is classified as FDA Pregnancy Category C. In the first trimester, there is limited data but a potential risk of gastroschisis has been suggested in some r. COLESTIPOL HYDROCHLORIDE is classified as Category C. Colestipol hydrochloride is not absorbed systemically, thus no direct fetal exposure. No teratogenic risk expected. First trimester: minimal risk. Second/third trimester: no known . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.